The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 30, 2021
Filed:
Aug. 29, 2017
Applicant:
Institut Pasteur, Paris, FR;
Inventors:
Lucie Peduto, Paris, FR;
Gerard Eberl, Paris, FR;
Assignee:
INSTITUT PASTEUR, Paris, FR;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C12N 15/113 (2010.01); A61K 38/48 (2006.01); G01N 33/573 (2006.01); G01N 33/68 (2006.01); A01K 67/027 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/6897 (2018.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A01K 67/0275 (2013.01); A61K 38/4886 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6897 (2013.01); G01N 33/573 (2013.01); G01N 33/6893 (2013.01); A01K 2217/203 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0368 (2013.01); A01K 2267/0393 (2013.01); C12N 15/8509 (2013.01); C12N 2015/859 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12N 2800/107 (2013.01); C12N 2820/55 (2013.01); C12Q 2600/158 (2013.01); C12Y 304/24 (2013.01); G01N 2333/96486 (2013.01); G01N 2500/00 (2013.01); G01N 2800/085 (2013.01); G01N 2800/12 (2013.01); G01N 2800/382 (2013.01);
Abstract
The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.